Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8f15e00c61cc673d8474e3c17a100b19 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1ac685ecdf1adb46406e81c66a9afde5 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2561-113 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0639 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0693 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-686 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-16 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-0784 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-09 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 |
filingDate |
2015-10-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cf51c5a1b180e0061bdbbbad1c4459f5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_229e535e06e23badb723e6a53641ba71 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_46f7fa84fcab72f5e03037958ab02d83 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7860544b042205f8c351d6e0804ca8eb |
publicationDate |
2017-04-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
KR-20170040996-A |
titleOfInvention |
Composition for cellular immunotherapy comprising cancer-testis antigen for prevention or treatment of Korean intractable multiple myeloma and preparation method thereof |
abstract |
The present invention relates to a composition for immune therapy or prevention of korean immature multiple myeloma cancer comprising cancer-testis antigens, wherein the dendritic cells loaded with the antigen and the cancer-testis antigen-specific cytotoxic T lymphocyte cells derived therefrom are effective A cytotoxic immune response in cancer immunotherapy can be induced by using a cell immunotherapeutic composition composition for preventing or treating multiple myeloma comprising the compound of the present invention as a vaccine for cancer therapy which is safe and has no side effects It is expected. |
priorityDate |
2015-10-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |